SCHEMBL4228728

SCHEMBL4228728

CCC(CC)NC(=O)Nc1ccc(Oc2ccc(NC(=O)c3ccc(OC45CCCC(CC4)N5C)cc3)c(F)c2)cc1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PKM P14618 2/20 0.38
MCHR1 Q99705 2/20 0.37
MCHR2 Q969V1 1/20 0.37
POLB P06746 1/20 0.35
MAPT P10636 1/20 0.35
HRH3 Q9Y5N1 2/20 0.35
TAS1R3 Q7RTX0 1/20 0.35
TAS1R1 Q7RTX1 1/20 0.35
DGAT1 O75907 1/20 0.34
KDR P35968 4/20 0.34
FLT1 P17948 3/20 0.34
FLT4 P35916 3/20 0.34
EPHB6 O15197 1/20 0.34
RIPK2 O43353 1/20 0.34
ABL1 P00519 1/20 0.34
NTRK1 P04629 1/20 0.34
LCK P06239 1/20 0.34
LYN P07948 1/20 0.34
RET P07949 1/20 0.34
MET P08581 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4228886 0.97 PKM (0.40) PKMMCHR1MCHR2POLBMAPT
SCHEMBL4787541 0.93 MCHR1 (0.36) PKMMCHR1MCHR2MAPTTAS1R3
SCHEMBL4226989 0.91 TAS1R3 (0.39) PKMMCHR1TAS1R3TAS1R1KDR
SCHEMBL4239015 0.91 PKM (0.43) PKMMCHR1MCHR2MAPTGAA
SCHEMBL4233302 0.88 PKM (0.38) PKMMCHR1MCHR2MAPTKDR
SCHEMBL4237744 0.84 PKM (0.38) PKMMCHR1MCHR2MAPTTAS1R3
SCHEMBL4238833 0.84 PKM (0.38) PKMMCHR1MCHR2POLBMAPT
SCHEMBL4236329 0.84 PKM (0.38) PKMMCHR1MCHR2MAPTTAS1R3
SCHEMBL4229247 0.84 MCHR1 (0.45) PKMMCHR1TAS1R3TAS1R1NPC1
SCHEMBL4237676 0.84 PNLIP (0.41) PKMMCHR1MCHR2MAPTNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090233910-A1 Npy antagonists, preparation and uses CEREP (FR) 2009-09-17 US claimed
US-20090233910-A1 Npy antagonists, preparation and uses CEREP (FR) 2009-09-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090233910-A1 Npy antagonists, preparation and uses NPY1R, NPY5R, NPY2R PKM 1734/4885MCHR1 47/4885MCHR2 30/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.